title: [Hepatitis B immunoglobulin treatment after liver transplantation--our experiences].
abstract: Liver transplantation was performed in 3 patients with hepatitis B infection in 1999-2004 years. Combination of hepatitis B immunoglobulin (HBIg) and lamivudine are used for prevention of hepatitis B recurrence. HBIg is administered in dose 2 000 international units (IU) with tendency to maintain anti-HBs antibodies above 100 IU/litre. Average interval between HBIg administrations was 22, 32 and 32 days, yearly price of treatment was 0.45-0.65 million Czech crowns. Three patients with HBIg and lamivudine therapy are still without recurrence of hepatitis B at the end of 2006 year.
authors.affiliation: Department of Infectious Diseases, University Hospital Ostrava, 17. listopadu 1790, 708 00 Ostrava, Czech Republic. ludek.roznovsky@fnspo.cz
authors.forename: L
authors.initials: L
authors.lastname: Roznovský
authors.forename: A
authors.initials: A
authors.lastname: Kloudová
authors.forename: L
authors.initials: L
authors.lastname: Kabieszová
authors.forename: V
authors.initials: V
authors.lastname: Dedek
authors.forename: I
authors.initials: I
authors.lastname: Orságová
authors.forename: A
authors.initials: A
authors.lastname: Zjevíková
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D006509:Hepatitis B / Q000517:prevention & control* / Q000601:surgery; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use; D016031:Liver Transplantation; D008297:Male; D055502:Secondary Prevention
chemical_list: D000998:Antiviral Agents; D007136:Immunoglobulins; D019259:Lamivudine; C045213:hepatitis B hyperimmune globulin